In vivo evaluation of the biodistribution of intravenously administered naked and functionalised silver nanoparticles in rabbit

Ayesha Ashraf; Rehana Sharif; Munir Ahmad; Misbah Masood; Abubakar Shahid; Dalaver H. Anjum; Muhammad Shahid Rafique; Sheeba Ghani

In vivo evaluation of the biodistribution of intravenously administered naked and functionalised silver nanoparticles in rabbit

View Fulltext

Author(s): Ayesha Ashraf ¹ ; Rehana Sharif ¹ ; Munir Ahmad ² ; Misbah Masood ² ; Abubakar Shahid ² ; Dalaver H. Anjum ³ ; Muhammad Shahid Rafique ¹ ; Sheeba Ghani ¹
- Affiliations: 1: Physics Department, University of Engineering and Technology, Lahore, Pakistan ;
  2: Institute of Nuclear Medicine and Oncology (INMOL), Lahore, Pakistan ;
  3: Advanced Nanofabrication Imaging and Characterization Laboratory, King Abdullah University of Science and Technology, Thuwal/Jeddah, Saudi Arabia
Source: Volume 9, Issue 6, December 2015, p. 368 – 374
DOI: 10.1049/iet-nbt.2014.0075 , Print ISSN 1751-8741, Online ISSN 1751-875X

Received 15/12/2014, Accepted 03/06/2015, Revised 22/05/2015, Published 01/12/2015

Water-based suspension of silver nanoparticles (AgNPs) and dextran coated AgNPs (dextran–AgNPs) are fabricated and characterised for intravenous administration. A simple method for radiolabelling of nanoparticles with ^99mTc was used. Labelling efficiency for AgNPs and dextran–AgNPs was found to be more than 80 and 88%, respectively. In vivo tissue uptake of nanoparticles during dynamic phase, after systematic administration by biodistribution analysis with single-photon emission computed tomography imaging has been evaluated. Biodistribution analysis revealed that ^99mTc–AgNPs and ^99mTc–dextran–AgNPs are mainly accumulated in liver/spleen region but ^99mTc–dextran–AgNPs delayed recognition and uptake by liver. Results indicate that dextran–AgNPs are able to evade reticuloendothelum system with enhanced blood retention time. Accumulation of nanoparticles in liver/spleen region implicates the utilisation of AgNPs for liver cancer treatment.

References

1. 1)
  - 2. Patil, M., Mehta, D.S., Guvva, S.: ‘Future impact of nanotechnology on medicine and dentistry’, J. Indian Soc. Periodontol., 2008, 12, (2), pp. 34–40 (doi: 10.4103/0972-124X.44088).
2. 2)
  - 24. Tong, M.C., Chen, W., Sun, J., Ghosh, D., Chen, S.: ‘Dithiocarbamate-capped silver nanoparticles’, J. Phys. Chem. B, 2006, 110, (39), pp. 19238–19242 (doi: 10.1021/jp0631174).
3. 3)
  - 1. Huang, D., Liao, F., Molesa, S., Redinger, D., Subramanian, V.: ‘Plastic-Compatible low resistance printable gold nanoparticle conductors for flexible electronics’, J. Electrochem. Soc., 2003, 150, (7), pp. G412–G417 (doi: 10.1149/1.1582466).
4. 4)
  - 10. Garza-Ocanas, L., Ferrer, D.A., Burt, J., et al: ‘Biodistribution and long-term fate of silver nanoparticles functionalized with bovine serum albumin in rats’, Metallomics, 2010, 2, (3), pp. 204–210 (doi: 10.1039/B916107D).
5. 5)
  - 9. Alivisatos, P.: ‘The use of nanocrystals in biological detection’, Nat. Biotechnol., 2004, 22, (1), pp. 47–52 (doi: 10.1038/nbt927).
6. 6)
  - 4. Conde, J., Doria, G., Baptista, P.: ‘Noble metal nanoparticles applications in cancer’, J. Drug Deliv., 2012, 2012, (doi: 10.1155/2012/751075).
7. 7)
  - 5. Yanyan, Z., Xuemei, W.: ‘Study on synergistic effect of new functionalized Ag nanoparticles for intracellular drug uptake in cancer cells’, Nano Biomed. Eng., 2010, 2, (4), pp. 208–213.
8. 8)
  - 27. Klein, J.: ‘Probing the interactions of proteins and nanoparticles’, Proc. Natl. Acad. Sci. USA, 2007, 104, (7), pp. 2029–2030 (doi: 10.1073/pnas.0611610104).
9. 9)
  - 22. Purushotham, S., Ramanujan, R.V.: ‘Modeling the performance of magnetic nanoparticles in multimodal cancer therapy’, J. Appl. Phys., 2010, 107, (11), p. 114701 (doi: 10.1063/1.3432757).
10. 10)
  - 30. Hou, Y., Liu, Y., Chen, Z., Gu, N., Wang, J.: ‘Manufacture of IRDye800CW-coupled Fe(3)O(4) nanoparticles and their applications in cell labeling and in vivo imaging’, J. Nanobiotechnol., 2010, 8, p. 25 (doi: 10.1186/1477-3155-8-25).
11. 11)
  - 31. Kim, J.S., Kuk, E., Yu, K.N., et al: ‘Antimicrobial effects of silver nanoparticles’, Nanomed. Nanotechnol. Biol. Med., 2007, 3, (1), pp. 95–101 (doi: 10.1016/j.nano.2006.12.001).
12. 12)
  - 28. Owens, D.E., Peppas, N.A.: ‘Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles’, Int. J. Pharm., 2006, 307, (1), pp. 93–102 (doi: 10.1016/j.ijpharm.2005.10.010).
13. 13)
  - 12. Banerjee, T., Singh, A.K., Sharma, R.K., Maitra, A.N.: ‘Labeling efficiency and biodistribution of technetium-99 m labeled nanoparticles: interference by colloidal tin oxide particles’, Int. J. Pharm., 2005, 289, (1-2), pp. 189–195 (doi: 10.1016/j.ijpharm.2004.09.022).
14. 14)
  - 17. Tolaymat, T.M., El Badawy, A.M., Genaidy, A., Scheckel, K.G., Luxton, T.P., Suidan, M.: ‘An evidence-based environmental perspective of manufactured silver nanoparticle in syntheses and applications: a systematic review and critical appraisal of peer-reviewed scientific papers’, Sci. Total Environ., 2010, 408, (5), pp. 999–1006 (doi: 10.1016/j.scitotenv.2009.11.003).
15. 15)
  - 23. Lah, N.A.C., Johan, M.R.: ‘Optical and thermodynamic studies of silver nanoparticles stabilized by Daxad 19 surfactant’, IJMR, 2011, 102, (3), pp. 340–347 (doi: 10.3139/146.110478).
16. 16)
  - 25. Ferrer, M.C.C., Ferrier, R.C., Eckmann, D.M., Composto, R.J.: ‘A facile route to synthesize nanogels doped with silver nanoparticles’, J. Nanopart. Res., 2012, 15, p. 1323 (doi: 10.1007/s11051-012-1323-5).
17. 17)
  - 11. Lankveld, D.P.K., Oomen, A.G., Krystek, P., et al: ‘The kinetics of the tissue distribution of silver nanoparticles of different sizes’, Biomaterials, 2010, 31, (32), pp. 8350–8361 (doi: 10.1016/j.biomaterials.2010.07.045).
18. 18)
  - 6. Behera, S., Debata, A., Nayak, P.L.: ‘Biomedical applications of silver nanoparticles’, J. Asian Sci. Res., 2011, 1, (1), pp. 27–56.
19. 19)
  - 15. Seo, Y.: ‘Quantification of SPECT and PET for drug development’, Curr. Radiopharm., 2008, 1, (1), pp. 17–21 (doi: 10.2174/1874471010801010017).
20. 20)
  - 7. Sevilla, P., Garcia-Blanco, F., Garcia-Ramos, J.V., Sanchez-Cortes, S.: ‘Aggregation of antitumoral drug emodin on Ag nanoparticles: SEF, SERS and fluorescence lifetime experiments’, Phys. Chem. Chem. Phys., 2009, 11, (37), pp. 8342–8348 (doi: 10.1039/b903935j).
21. 21)
  - 29. Li, S.D., Huang, L.: ‘Pharmacokinetics and biodistribution of nanoparticles’, Mol. Pharma., 2008, 5, (4), pp. 496–504 (doi: 10.1021/mp800049w).
22. 22)
  - 31. Chrastina, A., Schnitzer, J.E.: ‘Iodine-125 radiolabeling of silver nanoparticles for in vivo SPECT imaging’, Int. J. Nanomed., 2010, 5, pp. 653–659.
23. 23)
  - 18. Dhaneshwar, S., Kandpal, M., Gairola, N., Kadam, S.: ‘Dextran: a promising macromolecular drug carrier’, Indian J. Pharm. Sci., 2006, 68, (6), pp. 705–714 (doi: 10.4103/0250-474X.31000).
24. 24)
  - 20. Ahmed, N., Sharma, S.: ‘Green synthesis of silver nanoparticles using extracts of Ananas comosus’, Green Sust. Chem., 2012, 4, (2), pp. 141–147 (doi: 10.4236/gsc.2012.24020).
25. 25)
  - 33. Cho, W.S., Cho, M., Jeong, J., et al: ‘Acute toxicity and pharmacokinetics of 13Â nm-sized PEG-coated gold nanoparticles’, Toxicol. Appl. Pharma., 2009, 236, (1), pp. 16–24 (doi: 10.1016/j.taap.2008.12.023).
26. 26)
  - 19. Hornig, S., Bunjes, H., Heinze, T.: ‘Preparation and characterization of nanoparticles based on dextran-drug conjugates’, J. Colloid Interface Sci., 2009, 338, (1), pp. 56–62 (doi: 10.1016/j.jcis.2009.05.025).
27. 27)
  - 16. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C.: ‘Factors affecting the clearance and biodistribution of polymeric nanoparticles’, Mol. Pharma., 2008, 5, (4), pp. 505–515 (doi: 10.1021/mp800051m).
28. 28)
  - 26. Khodadust, R., Unsoy, G., Yalcin, S., Gunduz, G., Gunduz, U.: ‘PAMAM dendrimer-coated iron oxide nanoparticles: synthesis and characterization of different generations’, J. Nanopart. Res., 2013, 15, (3), pp. 1–13.
29. 29)
  - 32. Schipper, M.L., Cheng, Z., Lee, S.W., et al: ‘microPET-Based biodistribution of quantum dots in living mice’, J. Nucl. Med., 2007, 48, (9), pp. 1511–1518 (doi: 10.2967/jnumed.107.040071).
30. 30)
  - 21. Mornet, S., Vasseur, S., Grasset, F., Duguet, E.: ‘Magnetic nanoparticle design for medical diagnosis and therapy’, J. Mater. Chem., 2004, 14, (14), pp. 2161–2175 (doi: 10.1039/b402025a).
31. 31)
  - 14. Vasquez, K.O., Casavant, C., Peterson, J.D.: ‘Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging’, PLoS One, 2011, 6, (6), p. e20594 (doi: 10.1371/journal.pone.0020594).
32. 32)
  - 3. Moreno-Mañas, M., Pleixats, R.: ‘Formation of Carbonâ̂’carbon bonds under catalysis by transition-metal nanoparticles’, Acc. Chem. Res., 2003, 36, (8), pp. 638–643 (doi: 10.1021/ar020267y).
33. 33)
  - 13. Boss, D.S., Olmos, R.V., Sinaasappel, M., Beijnen, J.H., Schellens, J.H.M.: ‘Application of PET/CT in the development of novel anticancer drugs’, Oncologist, 2008, 13, (1), pp. 25–38 (doi: 10.1634/theoncologist.2007-0097).

Login

Not registered yet?

Share

Tools

Login to add to favourites

Key

In vivo evaluation of the biodistribution of intravenously administered naked and functionalised silver nanoparticles in rabbit

References

Related content